BFGF ON LOWER EXTREMITY BLOOD FLOW IN PTS WITH INTERMITTENT CLAUDICATION

点击翻译按钮获取中文摘要

Preclinical studies have shown that basic fibroblast growth factor (bFGF), an angiogenic peptide, promotes collateral development in models of myocardial and hind limb ischemia. We assessed the safety of intra-arterial bFGF in patients with intermittent claudication, and studied its effects on calf blood flow. A double-blind, placebo-controlled, dose-escalation trial was conducted in claudication patients with ankle/brachial systolic index <0.8. Patients were randomly assigned to placebo (n=6), 10 mcg/kg of bFGF (provided by Scios, Inc., Mountainview, CA) (n=4), 30 mcg/kg of bFGF once (n=5) and 30 mcg/kg of bFGF twice (n=4). The study drug was infused into the femoral artery of the ischemic leg. Calf blood flow was measured with strain gauge plethysmography in the final 2 treated groups and in 4 placebo patients, prior to treatment, and at 1 and 6 months after treatment. Subjective changes in the degree of claudication were assessed by a questionnaire. Intra arterial bFGF was well tolerated. bFGF significantly improved calf blood flow at 1 month by 66 +/- 26% (mean +/- SEM), and at 6 months by 153 +/- 51% (n=9, P=0.002). The magnitude of increase in calf blood flow was greater in patients receiving 2 doses of bFGF compared to 1 dose of 30 mcg/kg. Flow did not change significantly in the placebo group. bFGF-treated patients reported subjective improvement in symptoms of claudication, in contrast to placebo patients. In patients with intermittent claudication, 2 intra-arterial doses of 30 mcg/kg bFGF are safe. Although a larger confirmatory trial is necessary, our results provide the first proof of concept in a randomized double-blinded, placebo-controlled trial that angiogenic therapy can result in enhanced collateral flow in patients with obstructive peripheral arterial disease.